BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giannitrapani L, Cervello M, Soresi M, Notarbartolo M, La Rosa M, Virruso L, D'Alessandro N, Montalto G. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci. 2002;963:46-52. [PMID: 12095927 DOI: 10.1111/j.1749-6632.2002.tb04093.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006;12:2563-8. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16.2563] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 66] [Article Influence: 4.3] [Reference Citation Analysis]
2 Won HS, Kim YA, Lee JS, Jeon EK, An HJ, Sun DS, Ko YH, Kim JS. Soluble interleukin-6 receptor is a prognostic marker for relapse-free survival in estrogen receptor-positive breast cancer. Cancer Invest 2013;31:516-21. [PMID: 23902164 DOI: 10.3109/07357907.2013.826239] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
3 Lan T, Chang L, Wu L, Yuan YF. IL-6 Plays a Crucial Role in HBV Infection. J Clin Transl Hepatol 2015;3:271-6. [PMID: 26807383 DOI: 10.14218/JCTH.2015.00024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
4 Huang Z, Fang J, Gu J, Yan Y, Zhou J. Development of a capture ELISA to determine kinetics of soluble CD25 following in vitro and in vivo stimulation of duck peripheral blood monocytes. Vet Immunol Immunopathol 2011;140:102-9. [PMID: 21216015 DOI: 10.1016/j.vetimm.2010.11.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
5 Théret N, Bouezzedine F, Azar F, Diab-Assaf M, Legagneux V. ADAM and ADAMTS Proteins, New Players in the Regulation of Hepatocellular Carcinoma Microenvironment. Cancers (Basel) 2021;13:1563. [PMID: 33805340 DOI: 10.3390/cancers13071563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, Jung HS. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60:686-693. [PMID: 22906998 DOI: 10.1016/j.cyto.2012.07.017] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 7.2] [Reference Citation Analysis]
7 Giraldez MD, Carneros D, Garbers C, Rose-John S, Bustos M. New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34211157 DOI: 10.1038/s41575-021-00473-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Chan SL, Chan AW, Chan AK, Jian P, Mo F, Chan CM, Mok K, Liu C, Chong CC, Chan AT, Mok T, Yeo W. Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver Int 2017;37:280-9. [DOI: 10.1111/liv.13218] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
9 Ahlberg K, Ekman T, Gaston-johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. The Lancet 2003;362:640-50. [DOI: 10.1016/s0140-6736(03)14186-4] [Cited by in Crossref: 341] [Cited by in F6Publishing: 99] [Article Influence: 18.9] [Reference Citation Analysis]
10 Zhang SC, Zheng YH, Yu PP, Min TH, Yu FX, Ye C, Xie YK, Zhang QY. Lentiviral vector-mediated down-regulation of IL-17A receptor in hepatic stellate cells results in decreased secretion of IL-6. World J Gastroenterol 2012;18:3696-704. [PMID: 22851861 DOI: 10.3748/wjg.v18.i28.3696] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
11 Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology. 2014;26:54-74. [PMID: 24552665 DOI: 10.1016/j.smim.2014.01.001] [Cited by in Crossref: 319] [Cited by in F6Publishing: 274] [Article Influence: 45.6] [Reference Citation Analysis]
12 Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ, Chan HL. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 2009;124:2766-2770. [PMID: 19267406 DOI: 10.1002/ijc.24281] [Cited by in Crossref: 135] [Cited by in F6Publishing: 130] [Article Influence: 11.3] [Reference Citation Analysis]
13 Lee HL, Jang JW, Lee SW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Han NI, Yoon SK. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep 2019;9:3260. [PMID: 30824840 DOI: 10.1038/s41598-019-40078-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
14 Gallucci RM, Sloan DK, O'Dell SJ, Reinke LA. Differential expression of liver interleukin-6 receptor-alpha in female versus male ethanol-consuming rats. Alcohol Clin Exp Res 2004;28:365-73. [PMID: 15084893 DOI: 10.1097/01.alc.0000118316.20560.0d] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
15 Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El-Shehaby AM, Abu-Shady MA. Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol. 2005;11:6624-6630. [PMID: 16425355 DOI: 10.3748/wjg.v11.i42.6624] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
16 Naseem S, Hussain T, Manzoor S. Interleukin-6: A promising cytokine to support liver regeneration and adaptive immunity in liver pathologies. Cytokine Growth Factor Rev 2018;39:36-45. [PMID: 29361380 DOI: 10.1016/j.cytogfr.2018.01.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
17 Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer 2011;57:275-82. [PMID: 21671363 DOI: 10.1002/pbc.22821] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
18 Cabrera R, Ararat M, Cao M, Xu Y, Wasserfall C, Atkinson MA, Liu C, Nelson DR. Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig Dis Sci. 2010;55:484-495. [PMID: 19714465 DOI: 10.1007/s10620-009-0955-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
19 Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, Cervello M, D'Alessandro N, Montalto G. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006;12:2563-2568. [PMID: 16688802 DOI: 10.3748/wjg.v12.i16] [Reference Citation Analysis]
20 Nascimento MM, Bruchfeld A, Suliman ME, Hayashi SY, Pecoits-Filho R, Manfro RC, Pachaly MA, Renner L, Stenvinkel P, Riella MC, Lindholm B. Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. Braz J Med Biol Res 2005;38:783-8. [PMID: 15917961 DOI: 10.1590/s0100-879x2005000500017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
21 Labbozzetta M, Notarbartolo M, Poma P, Giannitrapani L, Cervello M, Montalto G, D’Alessandro N. Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann N Y Acad Sci. 2006;1089:268-275. [PMID: 17261774 DOI: 10.1196/annals.1386.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
22 Hinterhuber G, Drach J, Riedl E, Böhler K, Ferenci P, Wolff K, Foedinger D. Paraneoplastic pemphigus in association with hepatocellular carcinoma. J Am Acad Dermatol. 2003;49:538-540. [PMID: 12963927 DOI: 10.1067/s0190-9622(03)01581-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Giannitrapani L, Soresi M, Giacalone A, Campagna ME, Marasà M, Cervello M, Marasà S, Montalto G. IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS. 2011;15:183-186. [PMID: 21329460 DOI: 10.1089/omi.2010.0093] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
24 Ribera J, Rodríguez-Vita J, Cordoba B, Portolés I, Casals G, Casals E, Jiménez W, Puntes V, Morales-Ruiz M. Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity associated to the portal vein endothelium of cirrhotic rats. PLoS One 2019;14:e0218716. [PMID: 31233564 DOI: 10.1371/journal.pone.0218716] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
25 Zhang Y, Zhang B, Zhang A, Li X, Liu J, Zhao J, Zhao Y, Gao J, Fang D, Rao Z. IL-6 upregulation contributes to the reduction of miR-26a expression in hepatocellular carcinoma cells. Braz J Med Biol Res 2013;46:32-8. [PMID: 23011405 DOI: 10.1590/s0100-879x2012007500155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
26 Tang S, Liu Z, Zhang Y, He Y, Pan D, Liu Y, Liu Q, Zhang Z, Yuan Y. Rather than Rs1800796 polymorphism, expression of interleukin-6 is associated with disease progression of chronic HBV infection in a Chinese Han population. Dis Markers 2013;35:799-805. [PMID: 24371367 DOI: 10.1155/2013/508023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
27 Yu Z, Liu W, Liu D, Fan L. The regulatory role of Hyper-IL-6 in the differentiation of myeloid and erythroid progenitors derived from human cord blood. Cell Immunol 2006;241:32-7. [PMID: 16934790 DOI: 10.1016/j.cellimm.2006.07.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Sachdeva M, Chawla YK, Arora SK. Immunology of hepatocellular carcinoma. World J Hepatol 2015;7:2080-90. [PMID: 26301050 DOI: 10.4254/wjh.v7.i17.2080] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 9.7] [Reference Citation Analysis]
29 Lokau J, Schoeder V, Haybaeck J, Garbers C. Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1704. [PMID: 31683891 DOI: 10.3390/cancers11111704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
30 Liu F, Zhang W, Yang F, Feng T, Zhou M, Yu Y, Yu X, Zhao W, Yi F, Tang W. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling. Sci Rep. 2016;6:21260. [PMID: 26879559 DOI: 10.1038/srep21260] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
31 Griesinger AM, Josephson RJ, Donson AM, Mulcahy Levy JM, Amani V, Birks DK, Hoffman LM, Furtek SL, Reigan P, Handler MH, Vibhakar R, Foreman NK. Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. Cancer Immunol Res 2015;3:1165-74. [PMID: 25968456 DOI: 10.1158/2326-6066.CIR-15-0061] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
32 Shakiba E, Ramezani M, Sadeghi M. Evaluation of serum interleukin-6 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis. Clin Exp Hepatol 2018;4:182-90. [PMID: 30324143 DOI: 10.5114/ceh.2018.78122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
33 D'Alessandro N, Poma P, Montalto G. Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful? World J Gastroenterol 2007;13:2037-43. [PMID: 17465444 DOI: 10.3748/wjg.v13.i14.2037] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
34 Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev 2007;21:1396-408. [PMID: 17510282 DOI: 10.1101/gad.1553707] [Cited by in Crossref: 403] [Cited by in F6Publishing: 383] [Article Influence: 28.8] [Reference Citation Analysis]
35 Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012;3:236-60. [PMID: 22470194 DOI: 10.18632/oncotarget.466] [Cited by in Crossref: 123] [Cited by in F6Publishing: 113] [Article Influence: 13.7] [Reference Citation Analysis]
36 Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci. 2006;97:439-447. [PMID: 16734720 DOI: 10.1111/j.1349-7006.2006.00197.x] [Cited by in Crossref: 216] [Cited by in F6Publishing: 192] [Article Influence: 14.4] [Reference Citation Analysis]
37 Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, Moratti R, Corazza GR. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol. 2008;19:353-358. [PMID: 17962206 DOI: 10.1093/annonc/mdm448] [Cited by in Crossref: 97] [Cited by in F6Publishing: 90] [Article Influence: 6.9] [Reference Citation Analysis]
38 Cha H, Lee EJ, Seong J. Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy. World J Gastroenterol 2017;23:2077-85. [PMID: 28373775 DOI: 10.3748/wjg.v23.i11.2077] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
39 Liu Y, Lin J. Blocking the IL-6-STAT3 signaling pathway: potential liver cancer therapy. Future Oncol 2011;7:161-4. [PMID: 21345134 DOI: 10.2217/fon.10.183] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]